CPRX earnings

Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026 CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported financial results for the first quarter of 2026 and provided a business update. Financial Highlights For the Three Months Ended March 31, 20262025% Change(In thousands, except per share data)   Product Revenue, net$149,343$141,400              5.6%FIRDAPSE Product Revenue, net$98,859$83,731            18.1%AGAMREE Product Revenu

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today. Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned. About Catalyst Pharmaceuticals, Inc.Catalyst Pharmac

CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026. Catalyst's management team will host a conference call and webcast on Tuesday, May 12, 2026, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate:May 12, 2026Time:8:30 AM ETUS/Canada Dial-in

Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3% FIRDAPSE® (amifampridine) Growth and 67.5% Growth of AGAMREE® (vamorolone), Reflecting Continued Adoption Full Year 2026 Total Revenues Expected to be Between $615 Million and $645 Million, Reflecting Confidence in Strength and Durability of FIRDAPSE and AGAMREE Franchises Promoted Product Revenue, Net Expected to Grow by 20% or More in 2026 Conference Call and Webcast to be Held on February 26, 2026, at 8:30 AM ET CORAL GABLES, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuti

CORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2025 financial results after the market close on Wednesday, February 25, 2026. Catalyst's management team will host a conference call and webcast on Thursday, February 26, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details Date:February 26, 2026Tim

Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence in Long-term Outlook Conference Call and Webcast to be Held on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today reported financial results for the third quarter of 2025 and provi

CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2025 financial results after the market close on Wednesday, November 5, 2025. Catalyst's management team will host a conference call and webcast on Thursday, November 6, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details Date:November 6, 2025Time:8:30 AM ET

Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year 2025 Total Revenue Guidance of $545 Million to $565 Million, Reflecting Broad-Based Growth and Sustained Demand FIRDAPSE® Q2 2025 Net Product Revenue of $84.8 Million, Up 9.7% YoY; First Half 2025 Net Product Revenue of $168.6 Million, a 16.9% Increase Over Prior Year, Underscoring Sustained Momentum and Confidence in Long-Term Growth AGAMREE® Q2 2025 Net Product Revenue of $27.4 Million, Up 212.9% YoY; First Ha

CORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2025 financial results after the market close on Wednesday, August 6, 2025. Catalyst's management team will host a conference call and webcast on Thursday, August 7, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details Date:August 7, 2025Time:8:30

Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f

CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025. Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: Time:   US/Canada Dial-in Number:Interna

Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb

CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025. Catalyst's management team will host a conference call and webcast on Thursday, February 27, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: February 27, 20

Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance Highlights Operational Excellence and Strong Commercial Execution FIRDAPSE® Q3 2024 Net Product Revenues of $79.3 Million, Representing a 19.7% YoY Increase AGAMREE® Q3 2024 Net Product Revenues of $15.0 Million, Demonstrating Early U.S. Launch Success FYCOMPA® Q3 2024 Net Product Revenues of $32.1 Million Q3 2024 GAAP Net Income of $43.9 Million, $0.35 Per Share Diluted Q3 2024 Non-GAAP Net Income of $71.1 Million, $0.57 Per Share Diluted Updating 2024 Full Year Total Revenue Guidance to Be

CORAL GABLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2024 financial results after the market close on Wednesday, November 6, 2024. Catalyst's management team will host a conference call and webcast on Thursday, November 7, 2024, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details  Date:November 7, 2024Time:8:30 AM ET

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with customers of CHF 14.1 million (H1-2023: CHF 3.9 million)Operating result of CHF -17.7 million (H1-2023: CHF -20.3 million) and net result of CHF -15.3 million (H1-2023: CHF -23.3 million)AGAMREE® (vamorolone) launched in Germany and Austria as first European markets; North America partner has launched in the U.S.Approval of AGAMREE in the UK for the treatment of Duchenne muscular dystrophy (DMD); new drug application (NDA) in DMD under regulatory priority review in China Cash and cash

Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of $122.7 Million, Representing a 23.2% YoY Increase FIRDAPSE® Q2 2024 Net Product Revenues of $77.4 Million, Reflecting Strong Organic 19.2% YoY Growth AGAMREE® Q2 2024 Net Product Revenues of $8.7 Million Demonstrates a Strong Start to U.S. Commercialization FYCOMPA® Q2 2024 Net Product Revenues of $36.5 Million, Representing a 5.7% YoY Increase Q2 2024 GAAP Net Income of $40.8 Million, $0.33 Per Share Diluted Q2 2024 Non-GAAP Net Income of $69.6 Million, $0.56 Per Share Diluted Reaffirming 2024 Total Revenue G

CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2024 financial results after the market close on Wednesday, August 7, 2024. Catalyst's management team will host a conference call and webcast on Thursday, August 8, 2024, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details Date:Time:US/Canada Dial-in Number:Inte

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures:        Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million)        Net result of CHF 54.8 million (2022: CHF -71.1 million)         Cash flow from operating activities of CHF 47.6 million (2022: CHF -29.8 million)Regulatory approvals in key territories – AGAMREE® (vamorolone) approved for Duchenne muscular dystrophy (DMD) treatm

CORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2024 financial results after the market close on Wednesday, May 8, 2024. Catalyst's management team will host a conference call and webcast on Thursday, May 9, 2024, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate:May 9, 2024Time:8:30 AM ETUS/Canada Dial-in

CORAL GABLES, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2023 financial results after the market close on February 28, 2024. Catalyst's management team will host a conference call and webcast the following morning, Thursday, February 29, 2024, at 8:30 AM ET, to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate:February 29,

     Third Quarter 2023 Total Net Revenues of $102.7 Million, a 79.4% Increase YOY Third Quarter 2023 GAAP Net Loss per Share of $(0.29) Diluted, Impacted by an $81.5 Million One Time Non-Recurring IPR&D Expense Related to the Acquisition of AGAMREE® License Third Quarter 2023 Non-GAAP Net Income of $55.9 Million, $0.49 per Share Diluted Reported U.S. FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy sNDA Seeking to Increase FIRDAPSE® Maximum Daily Dose to 100 mg Accepted for Filing by the FDA Two New FIRDAPSE Patents Have Recently been Allowed; Upon Issuance will be Posted to the FDA's Orange Book, Further Strengthening our Intellectual Property Portfolio

CORAL GABLES, Fla., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its third-quarter 2023 financial results after market close on Wednesday, November 8, 2023. Catalyst's management team will host a conference call and webcast the following morning, Thursday, November 9, 2023, at 8:30 AM ET, to discuss the Company's financial results and provide a corporate update. Conference Call & Webcast Details Date/Time:November 9, 2023, at 8:30 AM ETUS/Canada Dia

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from contracts with customers of CHF 3.9 million (H1-2022: CHF 6.3 million)Operating result of CHF -20.3 million (H1-2022: CHF -25.5 million) and net result of CHF -23.3 million (H1-2022: CHF -29.7 million)Review of vamorolone's regulatory filings (NDA, MAA) for Duchenne muscular dystrophy (DMD) treatment proceeding as planned, with potential approvals in Q4-2023 and first EU/U.S. launches planned for Q1-2024Strategic transactions completed in July 2023: North American (NA) license for vamorolone granted to Catalyst Pha

Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of $0.33 Compared to $0.20 for Q2 2022Achieved 2023 Second Quarter Non-GAAP EPS Diluted of $0.53 Compared to $0.28 for Q2 2022During Q3-23 Completed the Acquisition of the North American License for VamoroloneSubmitted sNDA for FIRDAPSE Seeking to Increase the Maximum Indicated Dose to 100 mg per DayCompleted the Integration of our FYCOMPA® Commercial and MSL TeamsRaising Full Year 2023 Total Revenue Guidance of Between $380 Million and $390 MillionConference Call and Webcast to be Held on August 10, 2

CORAL GABLES, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its second-quarter 2023 financial results after market close on Wednesday, August 9, 2023. Catalyst's management team will host a conference call and webcast the following morning, Thursday, August 10, 2023, at 8:30 AM ET, to discuss the Company's financial results and provide a corporate update. Conference Call & Webcast Details Date/Time:   August 10, 2023, at 8:30 AM ETUS/Canada Dia

Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters Catalyst's Rare Neuroscience Portfolio Granted FDA Fast Track, Orphan Drug Designation, and a PDUFA Action Date of October 26, 2023 Catalyst Expects to Launch Vamorolone in the U.S. Early in Q1 2024, Subject to Regulatory Approval CORAL GABLES, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today announced the completion of its acquisition from Santhera Pharmaceuticals Holdings ("Santhera") of an exclusive license for

Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted of $0.41 Per Share, an Increase of 128% YoY Affirms Full Year Total Revenue Guidance of Between $375 Million and $385 Million Forecasts Full-Year 2023 Non-GAAP Net Income of Between $195 Million and $205 Million FYCOMPA® Commercial and Medical Affairs Teams Onboard and Fully Engaged Recently Reported Positive Feedback From the FDA on Submission to Seek Approval of sNDA to Increase the Maximum Daily Dose of FIRDAPSE® From 80mg to 100mg Continuing Efforts to Acquire One or More Commercial or Late-S

CORAL GABLES, Fla., April 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its first-quarter 2023 financial results after market close on Wednesday, May 10, 2023. Catalyst's management team will host a conference call and webcast the following morning, Thursday, May 11, 2023, at 8:30 AM ET, to discuss the Company's financial results and provide a corporate update. Conference Call & Webcast Details Date/Time:May 11, 2023, at 8:30 AM ETUS/Canada Dial

Achieved Record 2022 Total Net Revenues of $214 Million, a 52% YoY Increase Achieved FIRDAPSE® Q4 2022 Net Product Revenues of $61 Million, a 59% YoY Increase Newly Acquired FYCOMPA® Product Expected to be Accretive to EBITDA and EPS in 2023 Reaffirming Forecast of 2023 Total Net Product Revenues, including FYCOMPA, of between $375 Million and $385 Million Recently Acquired Patents Further Strengthens FIRDAPSE Long-Term Commercial Potential to 2037 Actively Pursuing Opportunities to Further Diversify our Product Portfolio Ended 2022 with Cash and Cash Equivalents of $298 Million Company to Host a Conference Call and Webcast on Thursday, March 16, 2023, at 8

CORAL GABLES, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2022 financial results after the market close on Wednesday, March 15, 2023. Catalyst's management team will host a conference call and webcast the following morning, Thursday, March 16, 2023, at 8:30 AM ET, to discuss the Company's financial results and provide a corporate update. Conference Call & Webcast Details

Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million Q3 2022 GAAP Net Income of $22.7 Million ($0.22 per basic and $0.20 per diluted share), which Includes a One Time Charge of $4.1 Million Related to the Acquisition of Ruzurgi® Cash and Short-Term Investments Increased in Q3 2022 by $35.3 Million to $256.1 Million Non-GAAP Net Income for Q3 2022 of $28.6 Million ($0.28 per basic share and $0.26 per diluted share) Company to Host a Conference Call and Webcast on November 10, 2022, at 8:30 AM ET CORAL GABLES, Fla., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.

CORAL GABLES, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its third quarter 2022 financial results after market close on Wednesday, November 9, 2022. Catalyst's management team will host a conference call and webcast the following morning, Thursday, November 10, 2022, at 8:30 AM ET, to discuss the Company's financial results and provide a corporate update. Conference Call & Webcast Details Date/Time:November 10, 2022 at 8:30 AM ETUS/Canada Di

Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million, a 57.7% YoY Increase Cash and Short-Term Investments at June 30, 2022 were $220.8 Million, with No Funded Debt Completed Acquisition of Ruzurgi® U.S. and Mexico Commercial Rights Advanced Plans to Diversify Portfolio and Invest in Innovative Rare Disease Opportunities Provides Guidance that Full-Year 2022 Adjusted EBITDA to be Between $100-105 Million Listing New Orange Book Patent Potentially Extends FIRDAPSE Patent Protection to 2037 Company to Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM EDT CORAL GABLES, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst")

CORAL GABLES, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. Catalyst's management team will host a conference call and webcast the following morning, Wednesday, August 10, 2022, at 8:30 AM ET to discuss the Company's financial results and provide a corporate update. Conference Call & Webcast Details Date/Time:August 10, 2022, at 8:30 AM ETUS/Canad

Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE® Significant Cash Position of $198 Million and No Funded Debt Advanced Plans to Diversify and Invest in Innovative Rare Disease Opportunities Reaffirms FY 2022 Total Revenue Guidance of $195 Million to $205 Million Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30 AM ET CORAL GABLES, Fla., May 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patie

CORAL GABLES, Fla., April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its first-quarter 2022 financial results after market close on Tuesday, May 10, 2022. Catalyst's management team will host a conference call and webcast the following morning, Wednesday, May 11, 2022, at 8:30 AM ET, to discuss the Company's financial results and provide a corporate update. Conference Call & Webcast Details Date/Time:May 11, 2022, at 8:30 AM ETUS/Canada Dial-in Number:

Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE Long-Term Commercial Potential to 2034 Actively Pursuing Opportunities to Diversify Commercial and Development Portfolio Strong Cash and Investments Position of $191 Million and No Funded Debt Company to Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET CORAL GABLES, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel med

CORAL GABLES, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its fourth quarter and full-year 2021 financial results after market close on Wednesday, March 16, 2022. Catalyst's management team will host a conference call and webcast the following morning, Thursday, March 17, 2022, at 8:30 AM ET to discuss the Company's financial results and provide a corporate update. Conference Call & Webcast Details Date/Time:   

Continued Strong Financial and Operational Performance in the Third Quarter 2021FIRDAPSE® Revenue of $35.9 Million Increased 23.1% Compared to Third Quarter 2020Plans to Seek to Expand the U.S. Approval of FIRDAPSE To Include Pediatric LEMS PatientsStrong Cash Position $174.8 Million Supports Long-term Growth StrategyCompany to Host Quarterly Conference Call on November 10, 2021, at 8:30 AM ET CORAL GABLES, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, t

CORAL GABLES, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release its third quarter 2021 financial results after market close on Tuesday, November 9, 2021. Catalyst's management team will host a conference call and webcast the following morning, Wednesday, November 10, 2021, at 8:30 AM EST to discuss the Company's financial results and provide a corporate update. Conference Call & Webcast Details Date/Time: November 10, 20

-Q2 2021 Total Net Revenues of $36.4 Million Reflect Strong Quarter over Quarter Growth -Q2 2021 GAAP Net Income of $12.2 Million; Non-GAAP Net Income of $17.4 Million -$155.3 Million in Cash and Investments and no Funded Debt at End of Q2-2021 -Catalyst to Host Quarterly Conference Call at 8:30 AM ET Tomorrow CORAL GABLES, Fla., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the sec

CORAL GABLES, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release second quarter 2021 financial results after market close on Monday, August 9, 2021. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, August 10, 2021 to discuss the financial results and to provide a corporate update. Investors who wish to participate in the conference call may do so by dialing (877) 407